AU2004243541A1 - Compositions comprising gastrin compounds and their use in diabetes - Google Patents

Compositions comprising gastrin compounds and their use in diabetes Download PDF

Info

Publication number
AU2004243541A1
AU2004243541A1 AU2004243541A AU2004243541A AU2004243541A1 AU 2004243541 A1 AU2004243541 A1 AU 2004243541A1 AU 2004243541 A AU2004243541 A AU 2004243541A AU 2004243541 A AU2004243541 A AU 2004243541A AU 2004243541 A1 AU2004243541 A1 AU 2004243541A1
Authority
AU
Australia
Prior art keywords
composition
weeks
cells
gastrin
gastrin compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2004243541A
Other languages
English (en)
Inventor
Antonio Cruz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Waratah Pharmaceuticals Inc
Original Assignee
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/016660 external-priority patent/WO2003100024A2/en
Application filed by Waratah Pharmaceuticals Inc filed Critical Waratah Pharmaceuticals Inc
Publication of AU2004243541A1 publication Critical patent/AU2004243541A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2004243541A 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes Withdrawn AU2004243541A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/US2003/016660 2003-05-27
PCT/US2003/016660 WO2003100024A2 (en) 2002-05-24 2003-05-27 Treatment for diabetes
PCT/CA2004/000769 WO2004105780A2 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes

Publications (1)

Publication Number Publication Date
AU2004243541A1 true AU2004243541A1 (en) 2004-12-09

Family

ID=33488788

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004243541A Withdrawn AU2004243541A1 (en) 2003-05-27 2004-05-27 Compositions comprising gastrin compounds and their use in diabetes

Country Status (11)

Country Link
EP (1) EP1648495A2 (ja)
JP (1) JP2007513059A (ja)
CN (1) CN1829528A (ja)
AU (1) AU2004243541A1 (ja)
BR (1) BRPI0410710A (ja)
CA (1) CA2527186A1 (ja)
MX (1) MXPA05012605A (ja)
NO (1) NO20055582L (ja)
PL (1) PL379145A1 (ja)
RU (1) RU2005140518A (ja)
WO (1) WO2004105780A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520345A (ja) 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
DE60329724D1 (de) 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
WO2005072045A2 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US20100256061A1 (en) * 2007-03-02 2010-10-07 Antonio Cruz Gastrin compound for diabetes treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
WO1995019785A1 (en) * 1994-01-24 1995-07-27 Research Triangle Pharmaceuticals Ltd. Treatment for juvenile diabetes
JP2004520345A (ja) * 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
DE60326002D1 (de) * 2002-10-22 2009-03-12 Waratah Pharmaceuticals Inc Behandlung von diabetes.

Also Published As

Publication number Publication date
BRPI0410710A (pt) 2006-06-13
WO2004105780A3 (en) 2005-01-20
CN1829528A (zh) 2006-09-06
MXPA05012605A (es) 2006-02-22
NO20055582D0 (no) 2005-11-25
JP2007513059A (ja) 2007-05-24
WO2004105780A2 (en) 2004-12-09
RU2005140518A (ru) 2007-07-10
PL379145A1 (pl) 2006-07-24
NO20055582L (no) 2006-02-27
CA2527186A1 (en) 2004-12-09
EP1648495A2 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
AU2005207870B2 (en) The combined use of GLP-1 agonists and gastrin for regulating blood glucose levels
US20090117102A1 (en) Methods and compositions using CD3 agonists
US20130150291A1 (en) Therapeutic agents comprising insulin amino acid sequences
EP2186824A2 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002239384A1 (en) Chronic treatment regimen using glucagon-like insulinotropic peptides
UA65549C2 (uk) Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
PL190991B1 (pl) Zastosowanie peptydu
WO2007095737A1 (en) Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
CZ299059B6 (cs) Použití GLP-1 nebo jeho analogu pro lécbu infarktu myokardu
WO2014113434A1 (en) Therapeutic agents, compositions, and methods for glycemic control
EP1496924A2 (en) Treatment of gastroparesis
US20100144613A1 (en) Combined use of DPP-IV Inhibitors and Gastrin Compounds
US20090156494A1 (en) Compositions and methods comprising gastrin compounds
AU2004243541A1 (en) Compositions comprising gastrin compounds and their use in diabetes
EP1620464A1 (en) Combined use of keratinocyte growth factor agonists and gastrin compounds
US20100256061A1 (en) Gastrin compound for diabetes treatment
KR20060017617A (ko) 가스트린 화합물을 포함하는 조성물 및 이의 용도
TW201441253A (zh) 具有ｎ端電荷修飾之促胰島素肽衍生物
MXPA01003008A (es) Uso de peptido similar a glucagon 1 (glp-1) o analogos en el tratamiento de la crisis fulminante
PL191627B1 (pl) Zastosowanie peptydu GLP-1 do wytwarzania leku do leczniczego zmniejszania masy ciała u człowieka
MXPA99001871A (en) Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery

Legal Events

Date Code Title Description
MK12 Application lapsed section 141(1)/reg 8.3(2) - applicant filed a written notice of withdrawal